Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page
- Check4 days agoChange DetectedSystemic sclerosis was added as the disease term and Scleroderma removed where it referred to the same condition.SummaryDifference0.0%

- Check11 days agoChange DetectedNapoli, Italy 80138 was updated to Naples, Italy 80138 in the locations list.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check25 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3, limited to version metadata and not affecting study details or user-facing content.SummaryDifference0.0%

- Check47 days agoChange DetectedA Scleroderma topic tag was added, and a link to the Genetic and Rare Diseases Information Center was added to Resources. These changes improve discoverability and provide an additional information source for patients without altering the study details.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Revision: v3.4.2; deleted the Notice about funding lapse and operating status and the previous Revision: v3.4.1.SummaryDifference0.1%

Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.